Published in J Clin Psychiatry on September 01, 2005
Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA (2014) 1.44
Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis. Addiction (2016) 1.43
Effects of smoking abstinence, smoking cues and nicotine replacement in smokers with schizophrenia and controls. Nicotine Tob Res (2008) 1.15
Effects of cigarette smoking and abstinence on Stroop task performance. Psychopharmacology (Berl) (2007) 1.06
Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia. Psychopharmacology (Berl) (2008) 1.04
Cognitive function during nicotine withdrawal: Implications for nicotine dependence treatment. Neuropharmacology (2013) 0.98
Predictors of early abstinence in smokers with schizophrenia. J Clin Psychiatry (2008) 0.97
Ten critical reasons for treating tobacco dependence in inpatient psychiatry. J Am Psychiatr Nurses Assoc (2009) 0.91
A Review of Smoking Cessation in Bipolar Disorder: Implications for Future Research. J Dual Diagn (2012) 0.88
Neurocognitive endophenotypes in schizophrenia: modulation by nicotinic receptor systems. Prog Neuropsychopharmacol Biol Psychiatry (2013) 0.83
The effects of galantamine on psychopathology in chronic stable schizophrenia. Clin Neuropharmacol (2009) 0.81
Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia. Psychopharmacology (Berl) (2013) 0.80
Medications Development for the Treatment of Nicotine Dependence in Individuals with Schizophrenia. J Dual Diagn (2007) 0.79
Antidepressants for cognitive impairment in schizophrenia--a systematic review and meta-analysis. Schizophr Res (2014) 0.78
Randomized Controlled Trials of Add-On Antidepressants in Schizophrenia. Int J Neuropsychopharmacol (2015) 0.76
Effectiveness of a multi-component Smoking Cessation Support Programme (McSCSP) for patients with severe mental disorders: study design. Int J Environ Res Public Health (2013) 0.75
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry (2008) 9.00
A genomic storm in critically injured humans. J Exp Med (2011) 6.67
Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med (2015) 6.06
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
Identification of separable cognitive factors in schizophrenia. Schizophr Res (2004) 5.34
Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA (2013) 4.81
Coronary CT angiography versus standard evaluation in acute chest pain. N Engl J Med (2012) 4.72
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull (2005) 4.66
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry (2008) 4.02
Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab (2002) 3.85
Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res (2007) 3.79
Mortality among homeless adults in Boston: shifts in causes of death over a 15-year period. JAMA Intern Med (2013) 3.67
Application of genome-wide expression analysis to human health and disease. Proc Natl Acad Sci U S A (2005) 3.49
Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol (2006) 3.39
Behavior therapy for children with Tourette disorder: a randomized controlled trial. JAMA (2010) 3.28
Social smoking among US college students. Pediatrics (2004) 2.99
Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry (2007) 2.91
Measuring the loss of autonomy over nicotine use in adolescents: the DANDY (Development and Assessment of Nicotine Dependence in Youths) study. Arch Pediatr Adolesc Med (2002) 2.88
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Biosocial pathways to functional outcome in schizophrenia. Schizophr Res (2005) 2.65
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res (2006) 2.60
Comparison of the SpO2/FIO2 ratio and the PaO2/FIO2 ratio in patients with acute lung injury or ARDS. Chest (2007) 2.58
Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab (2003) 2.54
Assessment of community functioning in people with schizophrenia and other severe mental illnesses: a white paper based on an NIMH-sponsored workshop. Schizophr Bull (2006) 2.53
Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence. Biol Psychiatry (2010) 2.45
Social perception as a mediator of the influence of early visual processing on functional status in schizophrenia. Am J Psychiatry (2006) 2.42
Electrical impedance myography to assess outcome in amyotrophic lateral sclerosis clinical trials. Clin Neurophysiol (2007) 2.36
The unmet health care needs of homeless adults: a national study. Am J Public Health (2010) 2.36
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry (2005) 2.35
Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry (2006) 2.31
The treatment of smoking by US physicians during ambulatory visits: 1994 2003. Am J Public Health (2007) 2.28
Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry (2013) 2.24
Psychosocial factors in outcomes of heart surgery: the impact of religious involvement and depressive symptoms. Health Psychol (2004) 2.17
Tobacco-cessation services and patient satisfaction in nine nonprofit HMOs. Am J Prev Med (2005) 2.11
Nonconscious and conscious color priming in schizophrenia. J Psychiatr Res (2012) 2.08
Benchmarking outcomes in the critically injured trauma patient and the effect of implementing standard operating procedures. Ann Surg (2012) 2.07
A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol (2005) 2.07
A smoking cessation intervention for parents of children who are hospitalized for respiratory illness: the stop tobacco outreach program. Pediatrics (2003) 2.05
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry (2010) 1.99
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res (2008) 1.97
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res (2008) 1.95
Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry (2011) 1.93
Tobacco smoke exposure in a sample of Boston public housing residents. Am J Prev Med (2013) 1.93
Recollections and repercussions of the first inhaled cigarette. Addict Behav (2004) 1.92
Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry (2005) 1.91
Increased medial temporal lobe activation during the passive viewing of emotional and neutral facial expressions in schizophrenia. Schizophr Res (2005) 1.90
Is emotion processing a predictor of functional outcome in schizophrenia? Schizophr Bull (2003) 1.89
A survey of tobacco dependence treatment services in 36 countries. Addiction (2009) 1.88
The Consortium on the Genetics of Endophenotypes in Schizophrenia: model recruitment, assessment, and endophenotyping methods for a multisite collaboration. Schizophr Bull (2006) 1.88
A snapshot of smokers after lung and colorectal cancer diagnosis. Cancer (2012) 1.85
The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom (2003) 1.83
Affective traits in schizophrenia and schizotypy. Schizophr Bull (2008) 1.81
Social cognition in schizophrenia: relationships with neurocognition and negative symptoms. Schizophr Res (2006) 1.80
Measuring provider adherence to tobacco treatment guidelines: a comparison of electronic medical record review, patient survey, and provider survey. Nicotine Tob Res (2005) 1.77
Natural language processing in the electronic medical record: assessing clinician adherence to tobacco treatment guidelines. Am J Prev Med (2005) 1.77
Cigarette smoking and advice to quit in a national sample of homeless adults. Am J Prev Med (2010) 1.73
Effect on smoking cessation of switching nicotine replacement therapy to over-the-counter status. Am J Public Health (2002) 1.72
Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects. Biol Psychiatry (2004) 1.72
Geographic inequity in access to livers for transplantation. Transplantation (2011) 1.71
Does anhedonia in schizophrenia reflect faulty memory for subjectively experienced emotions? J Abnorm Psychol (2006) 1.71
Smoking cessation advice rates in US hospitals. Arch Intern Med (2011) 1.70
From perception to functional outcome in schizophrenia: modeling the role of ability and motivation. Arch Gen Psychiatry (2012) 1.68
Neurocognitive performance and functional disability in the psychosis prodrome. Schizophr Res (2006) 1.67
The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology (2007) 1.67
A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol (2007) 1.66
Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry (2004) 1.65
A survey of tobacco dependence treatment guidelines in 31 countries. Addiction (2009) 1.63
Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry (2005) 1.61
The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res (2004) 1.59
Abnormal bone mineral accrual in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab (2002) 1.58
Benchmarking outcomes in the critically injured burn patient. Ann Surg (2014) 1.58
Social cognition in schizophrenia, Part 2: 12-month stability and prediction of functional outcome in first-episode patients. Schizophr Bull (2011) 1.56
Determining when impairment constitutes incapacity for informed consent in schizophrenia research. Br J Psychiatry (2007) 1.56